Novartis on Monday exercised its option to license an RNA-targeting cardiovascular drug from Ionis Pharmaceuticals as the Swiss company aims to surround its heart-failure blockbuster Entresto with other medicines.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,